ICER to Assess Three Alzheimer’s Treatments at July 2022 Meeting
The Institute for Clinical and Economic Review (ICER) has announced an assessment the comparative clinical effectiveness and value of donanemab (Eli Lilly & Co.) and lecanemab (Eisai Inc.) for the treatment of Alzheimer’s Disease (AD), along with aducanumab (Aduhelm™, Biogen). The assessment will be publicly discussed in July 2022 during a meeting of the California Technology Assessment Forum (CTAF). Following a public comment period, a Revised Scoping Document was posted January 27, 2022.
The NMQF public comment noted that “African Americans are two to three times more likely than non-Hispanic Whites to develop AD; and, Latinos are 1.5 times as likely. These disparities exist throughout all phases of AD. It is estimated that by 2030, nearly 40 percent of all Americans living with AD will be Black or Latinx. In short, for communities of color in the United States – indeed worldwide – the stakes associated with ICER’s assessment of current and potential treatments for Alzheimer’s Disease cannot be higher.”
NMQF called ICER’s attention to President Biden’s Presidential Executive Order on Advancing Racial Equity and Support for Underserved Communities Through the Federal Government in which he states: “Our Nation deserves an ambitious whole-of-government equity agenda that matches the scale of the opportunities and challenges that we face. It is therefore the policy of my Administration that the Federal Government should pursue a comprehensive approach to advancing equity for all, including people of color and others who have been historically underserved, marginalized, and adversely affected by persistent poverty and inequality. Affirmatively advancing equity, civil rights, racial justice, and equal opportunity is the responsibility of the whole of our Government. Because advancing equity requires a systematic approach to embedding fairness in decision-making processes, executive departments and agencies (agencies) must recognize and work to redress inequities in their policies and programs that serve as barriers to equal opportunity.”
In closing, NMQF noted that, “As stated in the general provisions of President Biden’s Executive Order, “Independent agencies are strongly encouraged to comply with the provisions of this order.” The National Minority Quality Forum believes that the organizations and individuals who constitute ICER’s authorizing environment have an obligation to their stakeholders, members and beneficiaries to hold ICER’s methods, values, policy statements and value assessments to a correspondingly high and responsive standard. Failure to do so can result in harms – whether intentional or unintentional – that cannot be reversed. That is a risk not worth taking.”